search
Back to results

CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients (VIEWER)

Primary Purpose

Chronic Kidney Disease Stage 5, End Stage Renal Disease

Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
VIEWER virtual care platform
Sponsored by
University of Manitoba
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Chronic Kidney Disease Stage 5 focused on measuring telemonitoring, chronic kidney disease, suboptimal dialysis initiation, digital health

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: >18 years of age Patient or primary caregiver can read and speak English Patient or patients substitute decision maker is able to provide informed consent Patient or primary care giver cognitively and physically capable and willing to use the VIEWER mobile application and perform self-measurements (i.e. weight, BP, etc.) Have stage 5 CKD (2 measurements of eGFR <15ml/min/1.73m2); eGFR will be calculated with the CKD-EPI equation. Followed in a multidisciplinary CKD clinic Have >40% chance of beginning dialysis in the next 2 years based on the Kidney Failure Risk Equation Exclusion Criteria: Inability of self or caregiver assisted self-monitoring using VIEWER

Sites / Locations

  • Chronic Disease Innovation Centre, Seven Oaks HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Intervention Group

Control Group

Arm Description

Participants randomized to the intervention group will be provided with a wireless BP cuff, weight scale, transcutaneous O2 sat monitor, wearable motion tracker and mobile tablet with the VIEWER application. Patients will be trained to use the VIEWER platform either virtually or in person. Patients will be guided through a daily self-assessment routine via the app (BP, weight, O2 saturation, step count upload) and weekly ESAS-r survey. Participants will use the VIEWER platform for 12 months in addition to receiving usual care. Additionally, participants will complete the UK Kidney PREM score (adapted to CKD) and the Health related QOL using KDQOL-SF via REDCap or paper form at baseline, 3, 6, 9 and 12 months, and the System Usability Scale (SUS) at 12 months.

Participants randomized to the control group will continue to receive usual care either virtually via telephone or video call or in person depending on COVID-19 restrictions in place. Participants will complete the UK Kidney PREM score (adapted to CKD) and the Health related QOL using KDQOL-SF via REDCap or paper form at baseline, 3, 6, 9 and 12 months.

Outcomes

Primary Outcome Measures

Composite of first hospitalization or emergency department (ED) visit
It's defined as an inpatient admission to hospital or a visit to the emergency department, whatever is first". So, we will compare the time of the first hospital admission /and or ED visit between two groups.

Secondary Outcome Measures

All-cause mortality
The mortality rate will be compared between the intervention and control group.
Proportion of patients who have an acute inpatient initiation of dialysis.
the rate of patients who started dialysis in the intervention and control groups during 1 year of follow-up.
Frequency of Emergency Department Visit
The average frequency of ED visit will be compared in two study groups.
Frequency of formal clinic visits
The average frequency of formal clinic visits will be compared between two study groups
UK Kidney PREM score (adapted to CKD)
The UK Kidney Patient Reported Experience Measure is a validated, self-reported scale that focuses on how kidney patients experience care. The UK Kidney PREM used for this trial consists of questions abstracted from the 2019 Kidney PREM. Possible scores range from 1 (strongly disagree) to 10 (strongly agree). The average total scores will be compared between intervention and control group.
Health related QOL using KQOL-SF
Kidney Disease Quality of Life- Short Form is a self-reported measure developed for individuals with kidney disease and those on dialysis. It includes 43 kidney disease targeted items, and 36 items that provide a measure of physical and mental health and 1 overall health rating item ranging from 0 (worst possible health) to 10 (best possible health).The average total scores will be compared between intervention and control groups.
System Usability Scale (SUS)
The System Usability Scale measures the usability of a wide range of products and services including hardware and software. It consists of a 10 item questionnaire with 5 response options ranging from 1 (strongly disagree) to 5 (strongly agree). This will be assessed via focus groups held with a subset of patients.
Provider Perspectives towards intervention (qualitative) focus groups
Assessed via focus groups held with a subset of providers
Patient Perspectives towards intervention (qualitative) focus groups
Assessed via focus groups held with a subset of patients
Proportion of patients greater than 80% adherence
tracked via VIEWER app

Full Information

First Posted
August 16, 2021
Last Updated
February 2, 2023
Sponsor
University of Manitoba
search

1. Study Identification

Unique Protocol Identification Number
NCT05726526
Brief Title
CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients
Acronym
VIEWER
Official Title
A Pragmatic Randomized Controlled Trial of a CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 30, 2022 (Actual)
Primary Completion Date
June 30, 2025 (Anticipated)
Study Completion Date
June 30, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Manitoba

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The main purpose of this trial is to determine whether the addition of the VIEWER virtual care platform to usual care will lead to a reduction in composite emergency department (ED) visits and/or hospitalizations/or increase the perceived safety of virtual care among patients and providers.
Detailed Description
Background: Chronic Kidney Disease (CKD) is an increasingly prevalent condition that represents a major national public health burden. The health transition from advanced CKD to the start of dialysis is a period of heightened vulnerability for many patients. Our data has demonstrated that during the 30-day period before the start of dialysis, there is a 10-fold increase in Emergency Department (ED) visits and hospitalizations related to kidney failure and its complications. Importantly, this spike occurs despite patients having frequent contact with their nephrology healthcare teams. For stable CKD patients, virtual monitoring could facilitate the communication of accurate and reliable data between patients and providers helping to avoid unnecessary ED visits and facilitate more optimal dialysis starts. Design& Method: The VIEWER study is a national, pragmatic, multicenter randomized controlled trial across 6 Canadian sites. VIEWER is a CKD-specific virtual care platform that integrates data from a wireless Blood Presure (BP) cuff, weight scale, transcutaneous O2 sat monitor, and wearable motion tracker. The patient-facing component of VIEWER (patient portal), is a custom application based on a mobile tablet that guides patients through a daily self-assessment routine using the connected devices. BP measurements, weight and oxygenation (as surrogates of volume status), and step counts (as a surrogate of functional status), provide semi-continuous longitudinal data on patient physical status. Additionally, patients are prompted to fill out a weekly symptom survey (Edmonton Symptom Assessment Score- revised; ESAS-r), a validated instrument of kidney failure symptoms. Patient data and ESAS scores are automatically uploaded to fully PHIA/HIPPA compliant servers where they are made available to the patients' care team through a secure, web-based provider portal. Provider notifications (flags) are generated for out-of-range values (i.e. BP, weights for volume management) and a secure messaging component allows for direct patient-provider communication. Participants will be trained to use the VIEWER platform by a member of the research team. On the provider side, two members of the care team at each site will be trained as "superusers" of the provider portal. These users will check and respond as needed daily (Monday to Friday) for flags and patient messages, and will respond or communicate as needed to the health care team as per local clinic standard operating procedures. Trends in measurements will be reviewed at multidisciplinary team rounds, which typically occur weekly. During routine clinic visits, trends in all objective and subjective measures will be available to review to inform clinical decision making. Consistent with our pragmatic design, we will not be proscriptive in how monitoring data are interpreted; rather, we ask that care teams consider this enriched data stream and incorporate that information according to their own protocols and clinical judgement. Patients randomized to the control group will see their multidisciplinary CKD care teams as per usual care. Follow-up visits and Focus Groups: Patient Reported Experience Measures (PREM) and Kidney Disease Quality of Life-Short Form (KDQOL-SF) will be measured at baseline, 3, 6, 9 and 12 months in all paticipanats. Usability, acceptability, and patient and provider perspective on the intervention will be assessed at the end of the trial using the System Usability Scale (SUS). In addition, two virtual focus groups will be conducted at the end of the study with a subset of participants and healthcare providers who used the VIEWER platform. Statistical Methods:The primary outcome (time to first hospitalization or ED visit, censoring at dialysis or death) will be assessed using univariate Cox proportional hazards models and a Kaplan-Meier analysis with a log-rank test, as will the secondary outcomes of all-cause mortality, ED visits, hospitalization, and acute inpatient dialysis initiation. Change in overall PREM, KDQOL-SF and SUS scores will be assessed with two-sided t-test or Wilcoxon Rank Sum test as distributionally appropriate, and interpreted relative to their minimal important differences. All outcomes will be assessed at a two-sided alpha= 0.05. Subgroup analyses will be prespecified and limited to 1) eGFR greater or less than 10ml/min, 2) sex and gender (described below) 3) diabetes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Kidney Disease Stage 5, End Stage Renal Disease
Keywords
telemonitoring, chronic kidney disease, suboptimal dialysis initiation, digital health

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Eligible participants will be randomly allocated to the intervention group (usual care + the VIEWER virtual care platform) or the control group (usual care).
Masking
Outcomes Assessor
Masking Description
Given the nature of the intervention, patients and care providers will not be blinded; outcome assessment and statistical analysis will be blinded
Allocation
Randomized
Enrollment
340 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention Group
Arm Type
Experimental
Arm Description
Participants randomized to the intervention group will be provided with a wireless BP cuff, weight scale, transcutaneous O2 sat monitor, wearable motion tracker and mobile tablet with the VIEWER application. Patients will be trained to use the VIEWER platform either virtually or in person. Patients will be guided through a daily self-assessment routine via the app (BP, weight, O2 saturation, step count upload) and weekly ESAS-r survey. Participants will use the VIEWER platform for 12 months in addition to receiving usual care. Additionally, participants will complete the UK Kidney PREM score (adapted to CKD) and the Health related QOL using KDQOL-SF via REDCap or paper form at baseline, 3, 6, 9 and 12 months, and the System Usability Scale (SUS) at 12 months.
Arm Title
Control Group
Arm Type
No Intervention
Arm Description
Participants randomized to the control group will continue to receive usual care either virtually via telephone or video call or in person depending on COVID-19 restrictions in place. Participants will complete the UK Kidney PREM score (adapted to CKD) and the Health related QOL using KDQOL-SF via REDCap or paper form at baseline, 3, 6, 9 and 12 months.
Intervention Type
Device
Intervention Name(s)
VIEWER virtual care platform
Intervention Description
VIEWER is a tablet based, CKD specific home telemonitoring platform developed by our team of patients and researchers that integrates data from a wireless blood pressure cuff, weigh scale, transcutaneous O2 sat monitor and wearable motion tracker via a tablet and custom app.
Primary Outcome Measure Information:
Title
Composite of first hospitalization or emergency department (ED) visit
Description
It's defined as an inpatient admission to hospital or a visit to the emergency department, whatever is first". So, we will compare the time of the first hospital admission /and or ED visit between two groups.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
All-cause mortality
Description
The mortality rate will be compared between the intervention and control group.
Time Frame
12 months
Title
Proportion of patients who have an acute inpatient initiation of dialysis.
Description
the rate of patients who started dialysis in the intervention and control groups during 1 year of follow-up.
Time Frame
12 months
Title
Frequency of Emergency Department Visit
Description
The average frequency of ED visit will be compared in two study groups.
Time Frame
12 months
Title
Frequency of formal clinic visits
Description
The average frequency of formal clinic visits will be compared between two study groups
Time Frame
12 months
Title
UK Kidney PREM score (adapted to CKD)
Description
The UK Kidney Patient Reported Experience Measure is a validated, self-reported scale that focuses on how kidney patients experience care. The UK Kidney PREM used for this trial consists of questions abstracted from the 2019 Kidney PREM. Possible scores range from 1 (strongly disagree) to 10 (strongly agree). The average total scores will be compared between intervention and control group.
Time Frame
baseline, 3, 6, 9 and 12 months
Title
Health related QOL using KQOL-SF
Description
Kidney Disease Quality of Life- Short Form is a self-reported measure developed for individuals with kidney disease and those on dialysis. It includes 43 kidney disease targeted items, and 36 items that provide a measure of physical and mental health and 1 overall health rating item ranging from 0 (worst possible health) to 10 (best possible health).The average total scores will be compared between intervention and control groups.
Time Frame
baseline, 3,6,9 and 12 months
Title
System Usability Scale (SUS)
Description
The System Usability Scale measures the usability of a wide range of products and services including hardware and software. It consists of a 10 item questionnaire with 5 response options ranging from 1 (strongly disagree) to 5 (strongly agree). This will be assessed via focus groups held with a subset of patients.
Time Frame
12 months
Title
Provider Perspectives towards intervention (qualitative) focus groups
Description
Assessed via focus groups held with a subset of providers
Time Frame
12 months
Title
Patient Perspectives towards intervention (qualitative) focus groups
Description
Assessed via focus groups held with a subset of patients
Time Frame
12 months
Title
Proportion of patients greater than 80% adherence
Description
tracked via VIEWER app
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: >18 years of age Patient or primary caregiver can read and speak English Patient or patients substitute decision maker is able to provide informed consent Patient or primary care giver cognitively and physically capable and willing to use the VIEWER mobile application and perform self-measurements (i.e. weight, BP, etc.) Have stage 5 CKD (2 measurements of eGFR <15ml/min/1.73m2); eGFR will be calculated with the CKD-EPI equation. Followed in a multidisciplinary CKD clinic Have >40% chance of beginning dialysis in the next 2 years based on the Kidney Failure Risk Equation Exclusion Criteria: Inability of self or caregiver assisted self-monitoring using VIEWER
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Claudio Rigatto, MD
Phone
204-631-3834
Email
crigatto@sogh.mb.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Zahra Solati, PhD
Phone
204-631-3834
Email
zsolati@sogh.mb.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Claudio Rigatto, MD
Organizational Affiliation
University of Manitoba
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chronic Disease Innovation Centre, Seven Oaks Hospital
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R2V 3M3
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Reid Whitlock

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients

We'll reach out to this number within 24 hrs